BMS’ Opdivo (nivolumab) Receives NICE Recommendation as 1L Treatment for Rare Gastroesophageal Cancers

Shots:

The NICE has issued a final draft guidance recommending BMS’ Opdivo + CT as a treatment option for untreated HER2-, advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma in patients whose tumors express PD-L1 with a CPS of ≥5
The decision was based on the P-III (Checkmate-649) trial evaluating Opdivo (360mg, q3w or 240mg, q2w) + CT vs CT alone in patients which showed an improvement in OS & PFS, m-OS (14.4mos. vs 11.1mos.), m-PFS (8.31mos. vs 6.05mos.), significant OS benefit was also observed in PD-L1+ patients with CPS ≥1 & in the all-randomized population
The safety profile was consistent with the known safety profiles of the individual treatments & no new safety signals were reported

Ref: Nice | Image: BMS